Healthcare Industry News: ReCell
News Release - June 10, 2011
Avita Medical Reports Additional Market Acceptance of its ReCell(R) Spray-On-Skin(TM)ReCell® Spray-On-Skin™ Symposium with Live Workshop at “Cosmedica 2011” held in Germany
ReCell presented at Translational Regenerative Medicine Forum meeting in Washington, D.C.; Has the potential to “alter the way we graft humans forever” says Wake Forest School of Medicine researcher
ReCell® Spray-On-Skin featured in June issue of Modern Medicine
NORTHRIDGE, Calif., & CAMBRIDGE, United Kingdom--(Healthcare Sales & Marketing Network)-- Avita Medical Ltd. (ASX: AVH), the regenerative medicine company, announced today that it has successfully introduced its ReCell Spray-On-Skin to hundreds of clinicians at a special ReCell symposium held at the “Cosmedica 2011 Congress for Aesthetic & Surgical Medicine” held in Bochum, Germany.
The Company’s booth, displaying ReCell, was well visited by attendees of the Congress that included over 250 aesthetic surgeons and clinicians from throughout Europe and Russia.
The symposium included presentations demonstrating the use of ReCell from its initial introduction for the treatment of severe burns to the benefit that patients are today experiencing in diverse indications including reconstructive surgery (e.g., scar remodeling) and dermatology (e.g., treatment of hypo- and hyper- pigmentation as in vitiligo).
A live workshop procedure using ReCell Spray-On-Skin in combination with a CO2 fractional laser in treating existing hypertrophic dyspigmented scars was conducted by Professor R. Hoffmann, M.D., Chief, Hand and Plastic Surgery, Department of Plastic Surgery, Evangelisches Krankenhaus, Marienstr, Oldenburg, Germany. “Fractional lasers are widely used in the treatment of dermal defects yet have many serious shortcomings,” said Dr. William Dolphin, CEO of Avita Medical. “ReCell provides significant advantages for the patient and clinician over the use of laser alone, including improved aesthetic outcomes and recovery times.”
In other news, ReCell was presented at the Translational Regenerative Medicine Forum meeting in Washington, D.C., in May 2011 and is featured in the June issue of Modern Medicine. ReCell has the potential to "alter the way we graft humans forever” … the ReCell approach to wound-healing is "fabulously disruptive technology,” said James H. Holmes IV, M.D., F.A.C.S., from the podium last month. Dr. Holmes is the principal investigator of an ongoing clinical study of ReCell and assistant professor of surgery at Wake Forest University School of Medicine, Winston-Salem, N.C.
Dr. Holmes joined the faculty at Wake Forest School of Medicine in 2006 as an assistant professor of surgery and is currently the medical director of the Burn Center. He received a cross-appointment to the Wake Forest Institute of Regenerative Medicine in January 2008. Dr. Holmes has published multiple peer-reviewed articles and book chapters on all aspects of burn care. Dr. Holmes is currently active in burn surgery capacity and burn disaster management in the State of North Carolina. His current research interests range from all aspects of burn care to patient safety.
More than 3,500 patients have been treated with ReCell for treatment of burns, hypo- and hyper-pigmentation (e.g., Vitiligo, a common skin pigmentation disease), scar revisions (e.g., acne), and aesthetic skin rejuvenation procedures (e.g., wrinkle removal). Use of ReCell has been clinically demonstrated to improve outcomes, reduce morbidity, and reduce length of hospital stay and patient care costs.
ABOUT ReCell® SPRAY-ON-SKIN™
ReCell allows in-theater preparation of a spray-on suspension consisting of cells derived from a small (2x 2cm), thin (0.15-0.20mm) biopsy of a patient’s own skin that is sufficient to cover an area up to 80 times the size of the biopsy. The ReCell suspension contains basal keratinocytes, melanocytes, fibroblasts and Langerhans cells. The metabolically responsive epithelial cells migrate across the wound surface, leading to regeneration of skin of normal color and texture. ReCell requires only a minimal donor site and is immediately available as a cell-based spray at the patient’s bedside.
ReCell® is patented, CE-marked for Europe, TGA-registered in Australia, and SFDA-cleared in China. ReCell® is not available for sale in the United States; in the U.S. ReCell® is an investigational device limited by federal law to investigational use.
ABOUT AVITA MEDICAL LTD.
Avita Medical (www.avitamedical.com) is a publicly listed medical technology company that develops and distributes regenerative and tissue-engineered products for the treatment of a broad range of wounds, scars and skin defects. Using patented and proprietary tissue-culture, collection and application technology, the company is able to provide innovative treatment solutions derived from a patient’s own skin. The company’s lead product, ReCell® Spray-On-Skin, has been designed for use in a wide variety of burns, plastic, reconstructive and cosmetic procedures.
This news release may include forward-looking statements that involve risks and uncertainties. You can identify these statements by the use of words such as “anticipate”, “estimate”, “expect”, “project”, “potential”, “intend”, “plan”, “believe”, “target”, “may”, “assume” or similar expressions. These forward-looking statements speak only as at the date of this release and are based on management’s expectations and beliefs concerning future events. Forward-looking statements are necessarily subject to risks, uncertainties and other factors, many of which are outside the control of Avita Medical that could cause actual results to differ materially from such statements. Avita Medical makes no undertaking to subsequently update or revise the forward-looking statements made in this release to reflect events or circumstances after the date of this release. This document is intended to provide background information only and does not purport to make any recommendation upon which you may reasonably rely without taking further and more specific advice.
Source: Avita Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.